1.	Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C21005, 2010-018662-23, NCT01193257
2.	Phase III Study of Dose-Escalated Radiation Therapy and Standard Androgen-Deprivation Therapy (ADT) With a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus Dose-Escalated Radiation Therapy and Enhanced ADT With a LHRH Agonist and Steroid 17alpha-monooxygenase TAK-700 in Patients With High-Risk Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-1115, RTOG-1115, NCT01546987
3.	Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C21013, 2012-001539-30, NCT01666314
4.	Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C21012, 2012-000136-26, NCT01549951
5.	TAK-700 in Castration Resistant Prostate Cancer Phase: Phase II Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-1211, 2012-002122-67, NCT01658527